Page 538 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

10. INHIBITEURS DE L’AROMATASE 499

DOWSti I M. et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in post­
menopausal breast cancer : optimisation of therapeutic dose and route. Cancer
Research, 1987, 47, 1957-1961.
DOWSETT M. et al. Dose related endocrine effects and pharmacokinetics of oral and
intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer
patients. Cancer Research, 1989, 49,1306-1312.
DOWSETT M. et al. Endocrine, pharmacokinetic and clinical studies of the aromatase
inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (pyridoglutethimide) in postmeno­
pausal breast cancer patients. Br. J. Cancer, 1991,64, 887-894.
Drugs of the Future. Atamestane, 1992, 17, 867-870.
EBRAHIMIAN S. et al. Synthesis and biochemical studies of 7a-substituted androsta-
1,4-diene-3,17-diones as enzyme activated irréversible inhibitors of aromatase.
Steroids, 1993, 58, 414-422.
EVANS T.R. Phase I and endocrine study of exemestane (FCE 24304) a new aroma­
tase inhibitor, in postmenopausal women. Cancer Research, 1992, 52, 5933-5939.
FALKSON G. Fadrozole hydrochloride, a new non toxic aromatase inhibitor for the
treatment of patients with metastatic cancer. J. Steroid. Biochem. Molec. Biol.,
1992, 43, 161-165.
FURET P. Aromatase inhibitors : synthesis, biological activity and binding mode of
azole-type compounds. J. Med. Chem., 1993, 36,1393-1400.
GEELEN J.A.A. et al. ORG 33201 : A new highly sélective orally active aromatase inhi­
bitor. J. Steroid. Biochem. Molec. Biol., 1993, 44, 681-682.
GERVAIS M. et al. 6-hydroximinoandrostenedione, a new spécifie inhibitor of estrogen
biosynthesis and its effect on T47D human breast cancer cells. Anticancer
Research., 1993, 13, 383-388.
GOSS P.E. et al. Metabolism of the aromatase inhibitor 4-hydroandrostenedione
in vivo. Identification of the glucuronide as a major urinary métabolite in patients
and biliary métabolite in the rat. J. Steroid. Biochem., 1986, 24, 619-622.
GOSS P.E. et al. Treatment of advanced postmenopausal breast cancer with an aro­
matase inhibitor, 4-hydroxyandrostenedione : Phase II report. Cancer Research.,
1986, 46, 4823-4826.
HÔFFKEN K. Expérience with aromatase inhibitors in the treatment of advanced
breast cancer. Cancer Treatment Reviews, 1993,19 (b), 37-44.
IVESON T.J. et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS
20267 in healthy postmenopausal women. J. Clin. Endocrinol. Metab., 1993, 77,
324-331.
JOHNSTON J. O’NEAL et al. Biological characterization of A-ring steroids. J. Steroid.
Biochem. Molec. Biol., 1993, 44, 623-631.
KITAWAKI J. et al. Sélective aromatase inhibition by pyridoglutethimide, an analogue
of aminoglutéthimide. Acta Endocrinologica, 1990,122, 592-598.
KORZEKWA K.R. et al. Studies of the mecanism of aromatase and other cyrtochrome
P450 mediated deformylation reactions. J. Steroid. Biochem. Molec. Biol., 1993,
44, 367-373.
KREKELS M.D.W.G. et al. Aromatase inhibition by R 83842 the dextroisomer of R
76713 in JEG-3 choriocarcinoma grown in ovariectomized nude mice. J. Steroid.
Biochem. Molec. Biol., 1992, 41, 761-764.